

Stockholm, April 28, 2009

Clarification: Share Issue in SCN Registered in March

Through registration of the share issue which was carried out in January at the Swedish Companies Registration Office, the number of shares in Scandinavian Clinical Nutrition AB (SCN) increased with 1,780,000 shares from 16,023,284 to 17,803,284 shares during March, 2009.

The company only has one class of shares, and the number of voting rights is therefore the same as the number of shares in the company.

This information is published with reference to chapter 4, section 9 in the Swedish Financial Instruments Trading Act.

For more information, please contact:

Ulf Söderberg, CEO, us@scnutrition.com, +46 708 13 22 81

Jörn Erik Aas, Chairman of the Board, jea@scnutrition.com, +47 924 99 360

Scandinavian Clinical Nutrition AB (publ) works in R&D and distribution of clinically tested, scientifically documented products within the field of nutrition (nutraceuticals). Established in 2006, SCN maintains a product portfolio with established trademarks, such as CUUR, Coldizin, Immulina, Membra7 and Ledactin. Core competence and strategic alliances, within both R&D and sales, in combination with innovative and clinically proven products, create good conditions for profitable growth both in Sweden and internationally. The shares of SCN are traded under the ticker "SCN" on Oslo Axess (www.osloaxess.no) and NGM Equity (www.ngm.se). For more information, please visit www.scnutrition.com.